In line with these observations, our experiments with escalating doses of anti‐GPC3 CAR‐T cells delivered through portal vein injection revealed a dose‐dependent increase of serum IFN‐γ levels and a consistent correlation with the enhanced tumour infiltration of CAR‐T cells at higher CAR‐T cell doses (Figure 5I,J). The gene discussed is GPC3; the disease is neoplasm.